

Management of recurrence after local treatment

Poster Session 72

Monday, 27 March
14:00 - 15:30

Location: Room Paris, North Hall (Level 1)

Chairs: S. Joniau, Leuven (BE)
N. Mottet, Saint-Étienne (FR)
K. Touijer, New York (US)

Aims and objectives of this session

To evaluate the imaging and markers for recurrence and adjuvant or salvage treatments results.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

950 **External validation of a TCP model predicting PSA relapse after post-prostatectomy radiotherapy**
By: Broggi S.², Galla A.³, Saracino B.⁴, Faiella A.⁴, Fossati N.⁵, Gabriele D.³, Maggio A.³, Sanguineti G.⁴, Di Muzio N.¹, Briganti A.¹, Cozzarini C.¹, Fiorino C.²

Institutes:¹San Raffaele Scientific Institute, Dept. of Radiotherapy, Milan, Italy, ²San Raffaele Scientific Institute, Dept. of Medical Physics, Milan, Italy, ³Candiolo Cancer Institute - FPO, IRCCS, Dept. of Radiotherapy, Candiolo, Italy, ⁴Regina Elena National Cancer Institute, Dept. of Radiotherapy, Rome, Italy, ⁵San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy

951 **Genomic classifier augments the role of pathological features in identifying optimal candidates for adjuvant radiation therapy in patients with prostate cancer: Development and internal validation of a multivariable prognostic model**

By: Dalela D.¹, Santiago-Jimenez M.², Yousefi K.², Karnes J.³, Ross A.⁴, Den R.⁵, Freedland S.⁶, Schaeffer E.⁷, Dicker A.⁵, Menon M.¹, Briganti A.⁸, Abdollah F.¹

Institutes:¹Henry Ford Health System, Vattikuti Urology Institute, Detroit, United States of America, ²GenomeDx Biosciences, GenomeDx Biosciences, Vancouver, Canada, ³Mayo Clinic, Dept. of Urology, Rochester, United States of America, ⁴Johns Hopkins Hospital, James Buchanan Brady Urological Institute, Baltimore, United States of America, ⁵Sidney Kimmel Cancer Center, Thomas Jefferson University, Dept. of Radiation Oncology, Philadelphia, United States of America, ⁶Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Dept. of Surgery, Division of Urology, Los Angeles, United States of America, ⁷Northwestern University, Feinberg School of Medicine, Dept. of Urology, Chicago, United States of America, ⁸Vita Salute San Raffaele Hospital, Dept. of Urology, Milan, Italy

952 **Natural history of patients treated with salvage radiation therapy for rising PSA after radical prostatectomy: A long-term survival analysis**

By: Briganti A.¹, Fossati N.¹, Karnes J.², Boorjian S.², Colicchia M.², Bossi A.³, Cozzarini C.⁴, Fiorino C.⁴, Noris Chiorda B.⁴, Dell'Oglio P.¹, Gandaglia G.¹, Wiegel T.⁵, Shariat S.⁶, Goldner G.⁷, Joniau S.⁸, Battaglia A.⁸, Haustermans K.⁹, De Meerleer G.⁹, Fonteyne V.¹⁰, Ost P.¹⁰, Van Poppel H.⁵, Montorsi F.¹

Institutes:¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²Mayo Clinic, Dept. of Urology, Rochester, United States of America, ³Gustave Roussy Institute, Dept. of Radiation Oncology, Villejuif, France, ⁴Vita-Salute University San Raffaele, Dept. of Radiotherapy, Milan, Italy, ⁵University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany, ⁶Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁷Medical University of Vienna, Dept. of Radiation Oncology, Vienna, Austria, ⁸University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ⁹University Hospitals Leuven, Dept. of Radiotherapy, Leuven, Belgium, ¹⁰Ghent University Hospital, Dept. of Radiotherapy, Ghent, Belgium

- *953 **Identifying the optimal candidate for salvage lymph node dissection for nodal recurrence of prostate cancer: Results from a large, multi-institutional analysis**
By: Suardi N.¹, Briganti A.¹, Fossati N.¹, Dell'Oglio P.¹, Gandaglia G.¹, Colicchia M.², Karnes J.R.², Haidl F.⁸, Pfister D.⁸, Porres D.⁸, Heidenreich A.⁸, Gratzke C.⁷, Herlemann A.⁷, Stief C.⁷, Battaglia A.⁵, Everaerts W.⁵, Joniau S.⁵, Van Poppel H.⁵, Aksenov A.⁴, Osmonov D.K.⁴, Jünemann K.P.⁹, Abreu A.D.L.³, Almeida F.³, Fay C.⁶, Gill I.⁶, Mottrie A.M.¹⁰, Montorsi F.¹
Institutes:¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²Mayo Clinic, Dept. of Urology, Rochester, Minnesota, United States of America, ³Phoenix Imaging Center, Dept. of Urology, Phoenix, Arizona, United States of America, ⁴Department of Urology and Pediatric Urology, University Hospital Schleswig Holstein, Campus Kiel, Dept. of Urology, Kiel, Germany, ⁵University Hospitals Leuven, Urology, Dept of Development and Regeneration, Leuven, Belgium, ⁶Keck School of Medicine, University of Southern California, USC Institute of Urology, Catherine & Joseph Aresty Department of Urology, Los Angeles, California, United States of America, ⁷Ludwig-Maximilians-University, Dept. of Urology, Munich, Germany, ⁸University of Cologne, Dept. of Urology, Cologne, Germany, ⁹University Hospital Schleswig Holstein, Campus Kiel, Dept. of Urology and Pediatric Urology, Kiel, Germany, ¹⁰OLV Ziekenhuis Aalst, Belgium ORSI Academy, Dept. of Urology, Melle, Belgium
- 954 **Selection criteria for surveillance in patients with biochemical recurrence after radical prostatectomy**
By: Mikami H., Numao N., Yamamoto S., Hagiwara K., Uehara S., Takeda H., Inoue T., Ogawa M., Yuasa T., Masuda H., Fukui I., Yonese J.
Institutes:Cancer Institute Hospital, Japanese Foundation for Cancer Research, Dept. of Urology, Koto-Ku, Japan
- 955 **Adjuvant versus early salvage radiation therapy in node positive prostate cancer patients: A long-term survival analysis**
By: Fossati N.¹, Karnes R.J.², Boorjian S.², Colicchia M.², Bossi A.³, Cozzarini C.⁴, Fiorino C.⁴, Chiorda B.N.⁴, Gandaglia G.¹, Dell'Oglio P.¹, Wiegel T.⁵, Shariat S.⁶, Goldner G.⁷, Joniau S.⁸, Battaglia A.⁸, Haustermans K.⁹, De Meerleer G.⁹, Fonteyne V.¹⁰, Ost P.¹⁰, Van Poppel H.⁵, Montorsi F.¹, Briganti A.¹
Institutes:¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²Mayo Clinic, Dept. of Urology, Rochester, United States of America, ³Gustave Roussy Institute, Dept. of Radiation Oncology, Villejuif, France, ⁴Vita-Salute University San Raffaele, Dept. of Radiotherapy, Milan, Italy, ⁵University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany, ⁶Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁷Medical University of Vienna, Dept. of Radiation Oncology, Vienna, Austria, ⁸University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ⁹University Hospitals Leuven, Dept. of Radiotherapy, Leuven, Belgium, ¹⁰Ghent University Hospital, Dept. of Radiotherapy, Ghent, Belgium
- 956 **Salvage external beam radiation therapy (EBRT) for local recurrence after high intensity focused ultrasound (HIFU) failure versus salvage HIFU for local recurrence after EBRT failure: A long term analysis**
By: Lee J-W.¹, Crouzet S.¹, Soria J.¹, Chapelon A.², Chapelon J.Y.², Melodelima C.³, Gal J.⁴, Pasticier G.⁵, Mege-Lechevallier F.⁶, Rouvière O.⁷, Gelet A.¹
Institutes:¹Hospices Civils De Lyon, Dept. of Urology and Transplantation, Lyon, France, ²Inserm, U1032, LabTau, Lyon, France, ³Laboratoire d'Ecologie Alpine, Grenoble, France, ⁴Centre Antoine Lacassagne, Dept. of Biostatistics, Nice, France, ⁵Pellegrin Hospital, Dept. of Urology and Transplantation, Bordeaux, France, ⁶Edouard Herriot Hospital, Dept. of Pathology, Lyon, France, ⁷Edouard Herriot Hospital, Dept. of Radiology, Lyon, France
- 957 **Predictive factors of positive 68Ga-PSMA PET/CT in patients with PSA recurrence following radical prostatectomy**
By: Tosco L.¹, Joniau S.¹, Witters M.¹, Battaglia A.¹, Cromphout L.², Goffin K.², Gheysens O.², Deroose C.², Oyen R.², Van Laere K.²
Institutes:¹Uz Leuven - Campus Gasthuisberg, Dept. of Urology, Leuven, Belgium, ²Uz Leuven - Campus Gasthuisberg, Dept. of Nuclear Imaging, Leuven, Belgium

- 958 **Clinical impact of 68Ga-PSMA PET/CT in prostate cancer patients with rising PSA after treatment with curative intent: Preliminary analysis of a multidisciplinary approach**
 By: [Albisinni S.](#)¹, Artigas C.², Aoun F.¹, Biau I.¹, Gil T.³, Hawaux E.¹, Limani K.¹, Otte F.X.⁴, Peltier A.¹, Sideris S.³, Sirtaine N.⁵, Flamen P.², Van Velthoven R.¹
Institutes:¹Institut Jules Bordet, Dept. of Urology, Brussels, Belgium, ²Institut Jules Bordet, Dept. of Nuclear Medicine, Brussels, Belgium, ³Institut Jules Bordet, Dept. of Oncology, Brussels, Belgium, ⁴Institut Jules Bordet, Dept. of Radiotherapy, Brussels, Belgium, ⁵Institut Jules Bordet, Dept. of Pathology, Brussels, Belgium
- 959 **68Ga-PSMA PET/CT improves biochemical response after salvage lymph node dissection for nodal recurrence in prostate cancer patients**
 By: [Herlemann A.](#)¹, Kretschmer A.¹, Buchner A.¹, Karl A.¹, Tritschler S.¹, El-Malazi L.¹, Wenter V.², Ilhan H.², Bartenstein P.², Stief C.¹, Gratzke C.¹
Institutes:¹Ludwig-Maximilians-University Munich, Dept. of Urology, Munich, Germany, ²Ludwig-Maximilians-University Munich, Dept. of Nuclear Medicine, Munich, Germany
- 960 **The comparison of prognoses between radiotherapy and radical prostatectomy in patients with high risk localized or locally advanced prostate cancer treated with neoadjuvant hormonal therapy**
 By: Joung J.Y.¹, Kim S.H.¹, Seo H.K.¹, [Chung J.](#)¹, Cho K.H.², Park W.S.³, Lee K.H.¹
Institutes:¹National Cancer Center, Dept. of Genitourinary Cancer Branch, Goyang, South Korea, ²National Cancer Center, Proton Therapy Center, Dept. of Radiation Oncology, Goyang, South Korea, ³National Cancer Center, Dept. of Pathology, Goyang, South Korea
- 962 **Stereotactic radiotherapy for bone and nodal oligometastases: Patterns of relapse in a prospective clinical trial**
 By: Siva S.², Udovicich C.¹, Shaw M.², Violet J.², Chander S.², Bressel M.³, Goad J.¹, Lawrentschuck N.¹, Foroudi F.¹, [Murphy D.](#)¹
Institutes:¹Peter Maccallum Cancer Centre, Dept. of Urology, Melbourne, Australia, ²Peter Maccallum Cancer Centre, Dept. of Radiation Oncology, Melbourne, Australia, ³Peter Maccallum Cancer Centre, Dept. of Biostatistics and Clinical Trials, Melbourne, Australia
- 963 **Assessing the risk of early and late toxicity of post-prostatectomy radiation therapy: A long-term multi-institutional analysis**
 By: [Briganti A.](#)¹, Fossati N.⁵, Karnes J.², Boorjian S.², Colicchia M.², Bossi A.³, Cozzarini C.⁴, Fiorino C.⁴, Noris Chiorda B.⁴, Dell'Oglio P.⁵, Gandaglia G.⁵, Wiegel T.⁶, Shariat S.⁷, Goldner G.⁸, Joniau S.⁹, Battaglia A.⁹, Haustermans K.¹⁰, De Meerleer G.¹⁰, Fonteyne V.¹¹, Ost P.¹¹, Van Poppel H.⁹, Montorsi F.⁵
Institutes:¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²Mayo Clinic, Dept. of Urology, Rochester, United States of America, ³Gustave Roussy Institute, Dept. of Urology, Villejuif, France, ⁴Vita-Salute University San Raffaele, Dept. of Radiotherapy, Milan, Italy, ⁵Vita-Salute University San Raffaele, Dept. of Oncology and Urology, Milan, Italy, ⁶University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany, ⁷Medical University of Vienna, Dept. of Oncology and Urology, Vienna, Austria, ⁸Medical University of Vienna, Dept. of Radiation Oncology, Vienna, Austria, ⁹University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ¹⁰University Hospitals Leuven, Dept. of Radiotherapy, Leuven, Belgium, ¹¹Ghent University Hospital, Dept. of Radiotherapy, Ghent, Belgium